Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Comparing efficacy of telehealth to in-person mental health care in intensive-treatment-seeking adults

Nyssa Z. Bulkes *, Kaley Davis, Brian Kay, Bradley C. Riemann

Rogers Behavioral Health System, 34700 Valley Rd., Oconomowoc, WI, USA, 53066

ARTICLE INFO

Keywords:
Behavioral health
Mental health
Telehealth
COVID-19

ABSTRACT

The heightened acuity in anxiety and depressive symptoms catalyzed by the COVID-19 pandemic presents an urgent need for effective, feasible alternatives to in-person mental health treatment. While tele-mental healthcare has been investigated for practicability and accessibility, its efficacy as a successful mode for delivering high-quality, high-intensity treatment remains unclear. This study compares the clinical outcomes of a matched sample of patients in a private, nation-wide behavioral health treatment system who received in-person, intensive psychological treatment prior to the COVID-19 pandemic (N = 1,192) to the outcomes of a distinctive group of patients who received telehealth treatment during the pandemic (N = 1,192). Outcomes are measured with respect to depressive symptoms (Quick Inventory of Depressive Symptomatology-Self-Report; QIDS-SR) and quality of life (Quality of Life Enjoyment and Satisfaction Questionnaire; Q-LES-Q). There were no significant differences in admission score on either assessment comparing in-person and telehealth groups. Patients in the partial hospitalization level of care stayed longer when treatment was remote. Results suggest telehealth as a viable care alternative with no significant differences between in-person and telehealth groups in depressive symptom reduction, and significant increases in self-reported quality of life across both groups. Future research is needed to replicate these findings in other healthcare organizations in other geographical locations and diverse patient populations.

1. Introduction

In response to the coronavirus disease 2019 (COVID-19) pandemic, healthcare organizations around the world adapted to remote behavioral health treatment to meet an increased need for high-quality mental health care. With lockdowns and stay-at-home orders, the pandemic presented an acute need for mental health treatment to be virtually accessible—regardless of patient or provider setting—as well as near-equivalent in quality to what a person would have received had they attended in person. This paper examines the current landscape of remote mental health care as a viable treatment delivery method and uses clinical outcomes data from patients undergoing in-person and telehealth mental health treatment at a large, multistate behavioral health system to illustrate telehealth’s comparability to traditional, in-person care.

The US Centers for Disease Control and Prevention (CDC) reported that symptoms of anxiety and depressive disorders among adults “increased considerably” when comparing reports from April through June of 2019 to the same time period in 2020 (Czeisler et al., 2020). In the survey with 5,412 adult respondents, the CDC measured anxiety and depressive symptoms related to the pandemic using the four-item patient health questionnaire (PHQ-4) and COVID-19 trauma-related symptoms using the six-item Impact of Event Scale. Overall, 40.9% of survey respondents reported at least one adverse mental health condition, including symptoms of anxiety disorder or depressive disorder (30.9%), and 26.3% reported symptoms of a trauma- and stressor-related disorder because of the pandemic. Suicidal ideation in the last 30 days was reported by 10.7% of respondents. In 2021, the CDC published results of the Household Pulse Survey, a self-report online survey, which showed that the percentage of adults who reported experiencing symptoms related to depression and anxiety disorders increased from 36.4% to 41.5% between August 2020 and February 2021 (Vahratian et al., 2021). Additionally, respondents who reported unmet mental health needs increased from 9.2% to 11.7% in the same time period. Historically there is evidence that mental health needs increase during a pandemic (Soklaridis et al., 2020). Past outbreaks, such as severe acute respiratory syndrome (SARS) in 2003, directly resulted in heightened anxiety related to the virus (Cheng and Cheung 2005;
mixed with respect to patient satisfaction of psychiatric telehealth services received in-person treatment are expected to show greater symptom reduction than patients who received telehealth treatment. However, consistent with the Zimmerman et al. (2021b) study, if the therapies employed translate as planned to the virtual format, we do not expect significant differences in scores at discharge comparing in-person and telehealth groups.

2. Methods

2.1. Participants and procedure

The Rogers Behavioral Health (Rogers) Institutional Review Board is committed to the ethical principles for the protection of human subjects in research which guide the IRB’s deliberations and decision-making, including respect for persons, beneficence, and justice. This study was approved with exempt determination by the Rogers Institutional Review Board (IRB). Because this study contained retrospective data analysis only and no prospective data collection, there was no consent process. Only de-identified data was used for analyses. All adult patients between 18 and 65 were eligible for inclusion. If patients were missing either an admission or discharge score for either of the two measures, they were excluded from analyses.

In March of 2020, following the onset of the COVID-19 pandemic, Rogers converted partial hospitalization (PHP) and intensive outpatient (IOP) treatment programs to telehealth. Prior to the pandemic, telehealth services were occasionally provided on an as-needed basis. The organization-wide transition to telehealth leveraged existing technological solutions for videoconferencing and scheduling sessions. If patients did not have a device to access their therapy sessions, laptops were provided. To ensure high-quality treatment, fidelity checks of treatment delivery were conducted by clinical supervisors and directors of clinical services. As pre-existing in-person treatment was protocolized and manualized, an existing audit process was leveraged to ensure compliance with treatment groups and to identify gaps in telehealth treatment delivery as compared to in-person care. Specific aspects of treatment delivery varied by services line (e.g., OCD PHP versus Depression Recovery PHP), however there was overlap in main treatment functions. Specifically, individual meeting invites were sent to each patient for every treatment element daily. Individual sessions included those with their assigned therapist and with their psychiatrists. Group sessions may have included cognitive behavioral therapy skills or possibly dialectal behavior therapy skills depending on the program the patient was enrolled in. Couples or family sessions were also delivered via telehealth. All treatment manuals and materials were sent electronically for patients to use during telehealth programming. Completed forms were emailed back to treatment team members to review in future sessions. Patients completed self-reported outcome measures in a protocolized fashion, at home, and all scores received from these assessments were integrated into the patient’s treatment. Close attention was paid to patient attendance for each treatment element and local police phone numbers and emergency contact information was collected and made accessible for all treatment team members in case someone did not appear for treatment in a timely manner. In addition to emergency contact information, safety protocols were developed to ensure response to safety concerns was timely and consistent.

The research study included in this submission aligns with the IRB-approved protocol. Participants include 2,384 adult patients who completed either PHP or IOP programs at Rogers, 1,192 patients in each of the in-person and telehealth groups. Patients in the telehealth group completed treatment between July 2020 and March 2021. The group of patients who received telehealth was matched to an equally sized sub-sample of 1,192 patients who received in-person care between May 2013 and December 2019. Groups were matched using optimal pairwise matching computed with the Matchit package in R (Ho et al., 2011), where covariates unrelated to treatment were balanced between in-person and telehealth groups. Covariates that were balanced in this way include age, sex, race, diagnosis, and level of care, ensuring that
Patients in PHP attend treatment 6 h per day, five days a week, and receive the same treatment content and frequency of treatment sessions regardless of when they completed treatment. In-person and telehealth providers participated in the same internal training program, ensuring a high level of similarity in treatment received by in-person and telehealth patient groups. Due to staff turnover, some providers were consistent across in-person and telehealth timeframes, whereas others were unique to one timeframe.

Two PROMs were used to index treatment efficacy: the Quick Inventory of Depressive Symptomology-Self Report (QIDS-SR; Rush et al., 2003) and the Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q; Schechter et al., 2007). Both assessments are administered upon admission, discharge, and either weekly or biweekly across all adult programs, service lines, and levels of treatment at Rogers. The Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR; Rush et al., 2003) is a 16-item self-report measure that asks respondents to indicate on a scale of 0–3 (0 = not at all, 3 = very much) how well each item describes them for the past week. The QIDS-SR assesses nine domains of depression symptomatology: sleep, mood, weight, concentration, guilt, suicidal ideation, interest, fatigue, and psychomotor changes. Responses are summed to provide a single outcome metric, which can range from 0 to 27, where a higher score indicates a more severe level of depression symptomatology. The Quality-of-Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q; Schechter et al., 2007) is a 16-item self-report measure that asks respondents to indicate on a scale of 1–5 (“very poor” = 1, “very good” = 5) how satisfied they have been across all adult programs, service lines, and levels of treatment at Rogers. The QIDS-SR and the Q-LES-Q are both measures that are widely used in clinical practice and research to assess treatment efficacy.
Table 3
Comparison of clinical assessment outcomes at admission and discharge for in-person and telehealth groups. Data are shown as mean ± standard deviation with analysis of variance results for the group factor.

| Clinical Assessment | Total Score | In-Person | Telehealth | Cohen’s D | F(1, 2380) | p   | η²  | Post-hoc comparisons |
|---------------------|-------------|-----------|------------|-----------|------------|-----|-----|---------------------|
| **QIDS**            |             |           |            |           |            |     |     |                     |
| ADMISSION           |             |           |            |           |            |     |     |                     |
| Treatment Delivery  |             | 14.15 ± 5.07 | 14.36 ± 5.27 | 1.06 | .30 | 0.00|     |                     |
| In-person           |             | 14.15 ± 5.07 |                  |     |     |     |     |                     |
| Telehealth          |             | 14.36 ± 5.27 |                  |     |     |     |     |                     |
| Level of Care       |             | 14.54 ± 5.04 | 14.95 ± 5.10 | 88.00 | <.001*** | 0.04|     |                     |
| PHP                 |             | 14.54 ± 5.04 |                  |     |     |     |     |                     |
| IOP                 |             | 14.95 ± 5.10 |                  |     |     |     |     |                     |
| Treatment Delivery  |             | 12.60 ± 4.87 | 12.04 ± 5.30 | 3.55 | .06 | 0.00|     |                     |
| × Level of Care     |             |                  |                  |     |     |     |     |                     |
| **DISCHARGE**       |             |           |            |           |            |     |     |                     |
| Treatment Delivery  |             | 8.42 ± 5.12 | 8.82 ± 5.27 | 3.60 | .06 | 0.00|     |                     |
| In-person           |             | 8.42 ± 5.12 |                  | 1.13 |     |     |     |                     |
| Telehealth          |             | 8.82 ± 5.27 |                  | 1.05 |     |     |     |                     |
| Level of Care       |             | 8.82 ± 5.14 | 9.15 ± 5.31 | 48.07 | <.001*** | 0.02|     |                     |
| PHP                 |             | 8.82 ± 5.14 |                  |     |     |     |     |                     |
| IOP                 |             | 9.15 ± 5.31 |                  |     |     |     |     |                     |
| Treatment Delivery  |             | 6.85 ± 4.71 | 7.49 ± 4.91 | 0.34 | .56 | 0.00|     |                     |
| × Level of Care     |             |                  |                  |     |     |     |     |                     |
| % CHANGE            |             |           |            |           |            |     |     |                     |
| Treatment Delivery  |             | -37.34% (37.38%) | -37.06% (37.47%) | 0.01 | .90 | 0.00|     |                     |
| In-person           |             | -37.34% (37.38%) |                  |     |     |     |     |                     |
| Telehealth          |             | -37.06% (37.47%) |                  |     |     |     |     |                     |
| Level of Care       |             | -36.50% (37.43%) | -37.04% (34.73%) | 0.00 | .96 | 0.00|     |                     |
| PHP                 |             | -36.50% (37.43%) |                  |     |     |     |     |                     |
| IOP                 |             | -37.04% (34.73%) |                  |     |     |     |     |                     |
| Treatment Delivery  |             | 44.64 ± 15.87 | 44.55 ± 15.94 | 2.67 | .10 | 0.00|     |                     |
| × Level of Care     |             |                  |                  |     |     |     |     |                     |
| **Q-LES-Q**         |             |           |            |           |            |     |     |                     |
| ADMISSION           |             |           |            |           |            |     |     |                     |
| Treatment Delivery  |             | 45.89 ± 16.07 | 46.22 ± 16.33 | 0.26 | .61 | 0.00|     |                     |
| In-person           |             | 45.89 ± 16.07 |                  |     |     |     |     |                     |
| Telehealth          |             | 46.22 ± 16.33 |                  |     |     |     |     |                     |
| Level of Care       |             | 44.64 ± 15.87 | 44.55 ± 15.94 | 78.00 | <.001*** | 0.03|     |                     |
| PHP                 |             | 44.64 ± 15.87 |                  |     |     |     |     |                     |
| IOP                 |             | 44.55 ± 15.94 |                  |     |     |     |     |                     |
| Treatment Delivery  |             | 50.78 ± 15.94 | 52.75 ± 16.22 | 1.59 | .21 | 0.00|     |                     |
| × Level of Care     |             |                  |                  |     |     |     |     |                     |
| **DISCHARGE**       |             |           |            |           |            |     |     |                     |
| Treatment Delivery  |             | 61.05 ± 17.62 | 61.67 ± 17.48 | 0.73 | .39 | 0.00|     |                     |
| In-person           |             | 61.05 ± 17.62 |                  | 0.90 |     |     |     |                     |
| Telehealth          |             | 61.67 ± 17.48 |                  | 0.91 |     |     |     |                     |
| Level of Care       |             | 59.73 ± 17.47 | 60.73 ± 17.71 | 39.14 | <.001*** | 0.02|     |                     |
| PHP                 |             | 59.73 ± 17.47 |                  |     |     |     |     |                     |
| IOP                 |             | 60.73 ± 17.71 |                  |     |     |     |     |                     |
| Treatment Delivery  |             | 66.23 ± 17.27 | 65.31 ± 16.07 | 1.17 | .28 | 0.00|     |                     |
| × Level of Care     |             |                  |                  |     |     |     |     |                     |
| % CHANGE            |             |           |            |           |            |     |     |                     |
| Treatment Delivery  |             | 21.46% (35.94%) | 21.06% (34.81%) | 1.62 | .20 | 0.00|     |                     |
| In-person           |             | 21.46% (35.94%) |                  |     |     |     |     |                     |
| Telehealth          |             | 21.06% (34.81%) |                  |     |     |     |     |                     |
| Level of Care       |             | 20.21% (42.93%) | 21.65% (36.79%) | 2.69 | .10 | 0.00|     |                     |
| PHP                 |             | 20.21% (42.93%) |                  |     |     |     |     |                     |
| IOP                 |             | 21.65% (36.79%) |                  |     |     |     |     |                     |
| Treatment Delivery  |             | 23.32% (34.81%) | 22.46% (34.81%) | 2.33 | .13 | 0.00|     |                     |
| × Level of Care     |             |                  |                  |     |     |     |     |                     |

Note: Significance threshold used is 0.05. F-statistics and partial eta-squared (η²) reflect the ANOVA results at the group level. T-tests reflect significant pairwise comparisons. Cohen’s D effect size reflects the change between admission and discharge score and is presented alongside discharge data only.

* Significantly greater.

% Change denotes percent change in total score (e.g. admission, discharge) over time.
from 0 to 100%, with higher percentages indicating greater enjoyment and satisfaction.

Statistical analyses were performed using R (R Core Team, 2021). To measure differences between in-person and telehealth groups, we conducted 2 x 2 between-subjects analyses of variance (ANOVA) with treatment modality (in-person, telehealth) and level of care (PHP, IOP) as independent variables. One ANOVA was conducted for each of total QIDS-SR score at admission, score at discharge, and percent change over time between admission and discharge. The same three tests were conducted for Q-LES-Q scores. Planned pairwise comparisons within each significant factor were conducted using t-tests (e.g. PHP compared to IOP). For all analyses, a two-tailed level of significance of 5% was adopted.

3. Results

There were no significant differences in admission score on either the QIDS-SR ($F(2380) = 1.06, p = .30$) or the Q-LES-Q ($F(2380) = 0.26, p = .61$) between in-person and telehealth groups (Table 3). For QIDS-SR scores, there was a significant main effect of level of care only at both admission ($F(1, 2380) = 88.00, p < .001$) and at discharge ($F(1, 2380) = 48.07, p < .001$). Planned pairwise comparisons showed that PHP scores at both time points, on average, were higher than IOP scores, which is clinically expected. The main effect of treatment delivery was trending but not significant at discharge only ($F(1, 2380) = 3.60, p = .06$) such that patients who received telehealth treatment had a higher average QIDS discharge score compared to in-person. The interaction between treatment delivery and level of care was not significant.

The same pattern of results seen for QIDS scores was also seen for Q-LES-Q scores, namely only a significant main effect of level of care at both admission ($F(2380) = 78.00, p < .001$) and at discharge ($F(2380) = 39.14, p < .001$). There was no main effect of treatment delivery or interaction between treatment delivery and level of care. Planned pairwise comparisons showed that Q-LES-Q admission and discharge scores were higher for patients in IOP relative to PHP, which is an expected result given the difference in degree of symptom severity at these different levels of care.

Pairwise Cohen’s $d$ effect sizes were calculated, as well as descriptive statistics for the change in QIDS-SR and Q-LES-Q scores from admission to discharge for all. Pairwise comparisons show the degree of change between admission and discharge scores comparing in-person and telehealth groups was not significant at either IOP or PHP levels of care for either QIDS-SR or Q-LES-Q. Effect sizes, overall, were moderate to high at all levels of care for both assessments. Length of stay was not significantly different comparing in-person and telehealth IOP groups ($t(481) = -1.66, p = .10$), but it was significantly different comparing PHP groups, such that patients receiving telehealth stayed 2.8 days longer in treatment than patients seen in person ($t(1877) = -6.62, p < .001$).

4. Discussion

To demonstrate the efficacy of telehealth treatment relative to in-person treatment, we compared clinical outcomes scores at admission and discharge for adult patients (1,192 in-person and 1,192 telehealth) across PHP and IOP programs. Patients who received PHP telehealth stayed an average of 2.8 days longer in treatment than the PHP in-person group; there was no difference in length of stay in IOP programs. This significant finding of increased length of stay in the PHP telehealth group is consistent with prior work (Zimmerman et al., 2021b). There were no significant differences in QIDS or Q-LES-Q discharge scores for either IOP or PHP groups, and there were no significant differences in the degree of change between admission and discharge scores for any group. Effect sizes were moderate to large across treatment modalities and levels of care. These data support remote treatment as a viable alternative to in-person mental health services, specifically as both in-person and remote patients experienced symptom reduction, and both populations reported improvements in quality of life.

There are recognized limitations of this study. Patients were not randomized into in-person and telehealth groups; rather, the external variable of the COVID-19 pandemic forced group membership in our sample. However, there were no between-group differences in QIDS-SR and Q-LES-Q admission scores at either the holistic level or by level of care, which suggests that no one group was more acute than the other at onset of treatment as indexed by these assessments. Further, matching in-person and telehealth groups for pre-treatment covariates—age, sex, race, and level of care—allowed us to examine the dependent variable of interest more closely, namely treatment outcomes, independent of these other factors. Additionally, findings are limited by the lack of a structured clinician-administered diagnostic assessment at admission which would strengthen the diagnoses established. However, licensed psychiatrists with years of experience diagnosing mental health disorders conducted the initial diagnostic assessments, and patient charts would be updated to reflect any changes to diagnoses made later in treatment.

Results have implications for both patients considering remote treatment options as well as organizations looking to implement alternatives to in-person care. Despite the differences in treatment delivery, our large sample size from a system-wide perspective supports telehealth as being as effective as in-person care for intensive-treatment-seeking individuals. For patients living far away from treatment centers or for patients who cannot leave home to attend in-person treatment, these results demonstrate telehealth treatment as a viable alternative to in-person treatment.

Author statement

Nyssa Z. Bulkes, Ph.D.: Methodology, Formal Analysis, Writing – Original Draft.
Kaley Davis, M.S.: Writing – Reviewing & Editing, Project Administration.
Brian Kay, Ph.D.: Resources, Writing – Reviewing & Editing, Conceptualization.
Bradley C. Riemann, Ph.D.: Resources, Writing – Reviewing & Editing, Conceptualization.

Declaration of competing interest

None.

References

American Psychiatric Association, 2013. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). American Psychiatric Pub.
Cheng, C., Cheung, M.W., 2005. Psychological responses to outbreak of severe acute respiratory syndrome: a prospective, multiple time-point study. J. Pers. 73 (1), 261–265.
Chong, J., Moreno, F., 2012. Feasibility and acceptability of clinic-based telepsychiatry for low-income Hispanic primary care patients. Telemed. e Health 18 (4), 297–304.
Chong, M.Y., Wang, W.C., Heeh, W.C., Lee, C.Y., Chiu, N.M., Yeh, W.C., et al., 2004. Psychological impact of severe acute respiratory syndrome on health workers in a tertiary hospital. Br. J. Psychiat. 185 (2), 127–133.
Cuevas, C.D.L., Arredondo, M.T., Cabrera, M.F., Sulzenbacher, H., Meise, U., 2006. Randomized clinical trial of telepsychiatry through videoconference versus face-to-face conventional psychiatric treatment. Telemed. e Health 12 (3), 341–350.
Czeisler, M.E., Lane, R.I., Petsosky, E., Wiley, J.F., Christensen, A., Njai, R., et al., 2020. Mental health, substance use, and suicidal ideation during the COVID-19 pandemic—United States, June 24–30, 2020. MMWR (Morb. Mortal. Wkly. Rep.) 69 (32), 1049.
Fruh, B.C., Henderson, S., Myrick, H., 2005. Telehealth service delivery for persons with alcoholism. J. Telemed. Telecare 11 (7), 372–375.
Hilty, D.M., Ferrer, D.C., Parish, M.B., Johnston, B., Callahan, E.J., Yellowlees, P.M., 2013. The effectiveness of telemental health: a 2013 review. Telemed. e Health 19 (6), 444–454.
Hs, D.E., Konge, I., King, G., Stuart, E.A., 2011. MatchIt: nonparametric preprocessing for parametric causal inference. J. Stat. Software 42 (8).
Hom, M.A., Weiss, R.B., Millman, Z.B., Christensen, K., Lewis, E.J., Cho, S., et al., 2020. Development of a virtual partial hospital program for an acute psychiatric population: lessons learned and future directions for telepsychotherapy. J. Psychother. Integrat. 30 (2), 365.
